SCHEMBL5630752

SCHEMBL5630752

CC(C)(CNCc1nonc1/C(=N\O)Nc1ccc(F)c(Cl)c1)N1CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
KMT2A Q03164 2/20 0.41
PIK3CD O00329 3/20 0.38
PIK3CB P42338 3/20 0.38
CYP3A4 P08684 3/20 0.38
AKT1 P31749 2/20 0.38
PIK3CG P48736 2/20 0.38
PIK3CA P42336 2/20 0.37
MAPK1 P28482 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.35
IDO1 P14902 1/20 0.34
MEN1 O00255 1/20 0.34
NAMPT P43490 1/20 0.34
HTT P42858 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5630763 1.00 LMNA (0.42) LMNAKMT2APIK3CDPIK3CBCYP3A4
SCHEMBL4981714 0.92 HPGD (0.40) LMNAKMT2ACYP3A4L3MBTL1SMN1; SMN2
SCHEMBL4981728 0.92 HPGD (0.40) LMNAKMT2ACYP3A4L3MBTL1SMN1; SMN2
SCHEMBL16582056 0.91 LMNA (0.40) LMNAKMT2APIK3CDPIK3CBCYP3A4
SCHEMBL14462764 0.89 LMNA (0.42) LMNAKMT2APIK3CDPIK3CBCYP3A4
SCHEMBL5630766 0.84 IDO1 (0.52) IDO1
SCHEMBL5631259 0.83 EGFR (0.47) LMNAKMT2AALDH1A1GAASMN1; SMN2
SCHEMBL5631270 0.83 EGFR (0.47) LMNAKMT2AALDH1A1GAASMN1; SMN2
SCHEMBL5630977 0.83 LMNA (0.42) LMNAKMT2APIK3CDPIK3CBCYP3A4
SCHEMBL5630964 0.83 LMNA (0.42) LMNAKMT2APIK3CDPIK3CBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971583-B1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORP (US) 2015-03-25 EP claimed
US-8951536-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2015-02-10 US claimed
US-20130177590-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2013-07-11 US claimed
US-8450351-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2013-05-28 US claimed
US-20070185165-A1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION 2007-08-09 US claimed
US-8951536-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2015-02-10 US disclosed
US-20130177590-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2013-07-11 US disclosed
US-8450351-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2013-05-28 US disclosed
US-20070185165-A1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130177590-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, HNMT LMNA 4520/4885KMT2A 545/4885PIK3CD 2533/4885
US-20070185165-A1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase IDO1, IDO2, HNMT LMNA 4520/4885KMT2A 545/4885PIK3CD 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.